AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Binaytara Awards $50K to Cancer Researchers: Impact Pitch
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.